Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25 + regulatory T cells in mice in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 553-561

  Wang, Da Wei ^a   Zhou, Rong Bin ^a   Yao, Yong Ming ^a   Zhu, Xiao Mei ^a   Yin, Yi Mei ^a   Zhao, Guang Ju ^a   Dong, Ning ^a   Sheng, Zhi Yong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; BUNGAROTOXIN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NICOTINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RECEPTOR BINDING; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANIMALS; ANTIGENS, CD; BUNGAROTOXINS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COCULTURE TECHNIQUES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; NICOTINE; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78649572256     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169961     Document Type: Article

References (39)

1. Aarts-Riemens T, Emmelot ME, Verdonck LF, and Mutis T (2008) Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells. Eur J Immunol 38:1381-1390.
2. Akdis CA and Akdis M (2009) Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 123:735-746.
3. Becker C, Taube C, Bopp T, Becker C, Michel K, Kubach J, Reuter S, Dehzad N, Neurath MF, Reifenberg K, et al. (2009) Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. Blood 114:1263-1269.
4. Belkaid Y (2008) Role of Foxp3-positive regulatory T cells during infection. Eur J Immunol 38:918-921.
5. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, and Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20-21.
6. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, and Ramsdell F (2001) Disruption of a new forkhead/ winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68-73.
7. De Rosa MJ, Esandi Mdel C, Garelli A, Rayes D, and Bouzat C (2005) Relationship between alpha 7 nAChR and apoptosis in human lymphocytes.J Neuroimmunol 160:154-161.
8. Dieckmann D, Plottner H, Berchtold S, Berger T, and Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303-1310.
9. Fontenot JD, Gavin MA, and Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330-336.
10. Gregori S, Bacchetta R, Passerini L, Levings MK, and Roncarolo MG (2007) Isolation, expansion, and characterization of human natural and adaptive regulatory T cells. Methods Mol Biol 380:83-105.
11. Kox M, van Velzen JF, Pompe JC, Hoedemaekers CW, van der Hoeven JG, and Pickkers P (2009) GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem Pharmacol 78:863-872.
12. Li L and Boussiotis VA (2008) Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences. Chem Immunol Allergy 94:178-188.
13. Lloyd GK and Williams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292:461-467.
14. Marinou M and Tzartos SJ (2003) Identification of regions involved in the binding of alpha-bungarotoxin to the human alpha7 neuronal nicotinic acetylcholine receptor using synthetic peptides. Biochem J 372:543-554.
15. McHugh RS, Shevach EM, and Thornton AM (2001) Control of organ-specific autoimmunity by immunoregulatory CD4(+)CD25(+) T cells. Microbes Infect 3:919-927.
16. Miyazawa A, Fujiyoshi Y, and Unwin N (2003) Structure and gating mechanism of the acetylcholine receptor pore. Nature 423:949-955.
17. Munn DH, Sharma MD, and Mellor AL (2004) Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172:4100-4110.
18. Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, Yang L, Valdés-Ferrer SI, Patel NB, Chavan S, Al-Abed Y, Yang H, and Tracey KJ (2009) The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 15:195-202.
19. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, Tracey KJ, Al-Abed Y, and Metz CN (2005) Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 201:1113-1123.
20. Schmidt EM, Wang CJ, Ryan GA, Clough LE, Qureshi OS, Goodall M, Abbas AK, Sharpe AH, Sansom DM, and Walker LS (2009) Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol 182:274-282.
21. Setoguchi R, Hori S, Takahashi T, and Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201:723-735.
22. Sheu BC, Chang WC, and Huang SC (2010) New era of regulatory T cells in tumor immunity: insights in cancer immunotherapy. J Formos Med Assoc 109:1-3.
23. Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30:636-645.
24. Shimizu J, Yamazaki S, and Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218.
25. Su L, Creusot RJ, Gallo EM, Chan SM, Utz PJ, Fathman CG, and Ermann J (2004) Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol 173:4994-5001.
26. Sun J, Madan R, Karp CL, and Braciale TJ (2009) Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 15:277-284.
27. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, and Sakaguchi S (1998) Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10:1969-1980.
28. Thornton AM and Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287-296.
29. Thornton AM and Shevach EM (2000) Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164:183-190.
30. Thornton AM, Donovan EE, Piccirillo CA, and Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519-6523.
31. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, and Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547.
32. Vignali D (2008) How many mechanisms do regulatory T cells need? Eur J Immunol 38:908-911.
33. Waldmann H, Adams E, Fairchild P, and Cobbold S (2008) Regulation and privilege in transplantation tolerance. J Clin Immunol 28:716-725.
34. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ, et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216-1221.
35. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421:384-388.
36. Wing K and Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7-13.
37. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, and Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271-275.
38. Zheng W, Wang QH, Feng H, Liu J, Meng HR, and Cao YM (2009) CD4+CD25+Foxp3+ regulatory T cells prevent the development of Th1 immune response by inhibition of dendritic cell function during the early stage of Plasmodium yoelii infection in susceptible BALB/c mice. Folia Parasitol 56:242-250.
39. Zhu X, Yang P, Zhou H, Li B, Huang X, Meng Q, Wang L, and Kijlstra A (2007) CD4+CD25+Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation. Graefes Arch Clin Exp Ophthalmol 245:1549-1557. (Pubitemid 47423338)